1790 related articles for article (PubMed ID: 26654227)
21. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
Hernandez-Ilizaliturri FJ; Czuczman MS
Oncology (Williston Park); 2009 May; 23(6):546-53. PubMed ID: 19544696
[TBL] [Abstract][Full Text] [Related]
22. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
24. [Advances in the Molecular Diagnosis and Therapy of Relapsed/Refractory Diffuse Large B-cell Lymphoma -Review].
Wang Y; Xia B; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):603-608. PubMed ID: 29665940
[TBL] [Abstract][Full Text] [Related]
25. Novel disease targets and management approaches for diffuse large B-cell lymphoma.
Wilson WH; Hernandez-Ilizaliturri FJ; Dunleavy K; Little RF; O'Connor OA
Leuk Lymphoma; 2010 Aug; 51 Suppl 1(Suppl 1):1-10. PubMed ID: 20658952
[TBL] [Abstract][Full Text] [Related]
26. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO; Mehta A
Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
[TBL] [Abstract][Full Text] [Related]
27. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
29. Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging.
Barré FPY; Claes BSR; Dewez F; Peutz-Kootstra C; Munch-Petersen HF; Grønbæk K; Lund AH; Heeren RMA; Côme C; Cillero-Pastor B
Anal Chem; 2018 Dec; 90(24):14198-14206. PubMed ID: 30422637
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
[TBL] [Abstract][Full Text] [Related]
31. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
Amin AD; Peters TL; Li L; Rajan SS; Choudhari R; Puvvada SD; Schatz JH
Cold Spring Harb Mol Case Stud; 2017 May; 3(3):a001719. PubMed ID: 28487884
[TBL] [Abstract][Full Text] [Related]
33. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.
Karmali R; Gordon LI
Curr Treat Options Oncol; 2017 Feb; 18(2):11. PubMed ID: 28229364
[TBL] [Abstract][Full Text] [Related]
34. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
[TBL] [Abstract][Full Text] [Related]
35. Tissue microarray in a subset of South African patients with DLBCL.
Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
[TBL] [Abstract][Full Text] [Related]
36. Targeted treatment and new agents in diffuse large B-cell lymphoma.
Leonard JP; Martin P; Barrientos J; Elstrom R
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S11-6. PubMed ID: 18760704
[TBL] [Abstract][Full Text] [Related]
37. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Yang X; Min X; He W
Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
39. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]